Pluri AAQS

Que fait Pluri ? Pluri Inc, listed under the ticker PLUR with ISIN US72942G2030, is a biotechnology company headquartered in Haifa, Israel. The company operates within the Health Care sector, specifically in the Biotechnology industry. Founded in 2007, Pluri Inc. went public on December 10, 2007. The company employs 123 people and maintains a website at https://pluri-biotech.com/. Pluri Inc. focuses on the development of cell therapies, with its lead indications targeting critical limb ischemia (CLI), recovery following surgery for femoral neck fracture, and acute radiation syndrome. The company's operations encompass research, development, clinical trials, and manufacturing of cell therapeutics and related technologies. Pluri's PLX-PAD and PLX R18 are among its product offerings. The PLX cells utilized by the company are adherent stromal cells (ASCs) expanded through a three-dimensional (3D) process that employs a synthetic scaffold to create an artificial 3D environment for placental-derived stromal cells to grow. These PLX products are administered via standard needle and syringe. The company's cell therapies are in clinical-stage development for various conditions, including cardiovascular, orthopedic, pulmonary, and women's health diseases. Pluri Inc. is engaged in advancing therapeutic solutions through innovative cell-based approaches, aiming to address significant unmet medical needs across multiple therapeutic areas. Pluri est l'une des entreprises les plus populaires sur Eulerpool.